rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2020-420-427rsp-2931Research ArticleПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕPROGRESS IN RHEUMATOLOGY IN THE XXI CENTURYПроблемы боли и качества жизни при ревматоидном артрите: фокус на барицитинибProblems of pain and quality of life in rheumatoid arthritis: focus on baricitinibhttps://orcid.org/0000-0002-1391-0711КаратеевА. Е.KarateevA. E.

доктор медицинских наук, зав. лабораторией патофизиологии боли и клинического полиморфизма скелетно-мышечных заболеваний,

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

aekarat@yandex.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202004092020584420427Copyright © Каратеев А.Е., 20202020Каратеев А.Е.Karateev A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2931

Современная патогенетическая терапия ревматоидного артрита (РА) позволяет не только снижать активность иммунного воспаления и замедлять прогрессирование болезни, но и обеспечивать максимально быстрое устранение основных симптомов, вызывающих наибольшее беспокойство пациентов – боли, нарушения функции, утомляемости. Таким действием обладает ингибитор янус-киназ 1 и 2 – барицитиниб (БАРИ), который быстро снижает активность воспаления, обеспечивает достижение ремиссии при РА, обладает высоким анальгетический потенциалом. В обзоре обсуждается роль аутоиммунного воспаления и внутриклеточного сигнального пути JAK/STAT (Janus kinase/signal transducers and activators of transcription) в патогенезе хронической боли при РА, роль БАРИ как средства для эффективного контроля интенсивности боли и усталости. 

Modern therapy for rheumatoid arthritis (RA) allows not only to reduce the activity of immune-mediated inflammation and slow down the progression of the disease, but also to quickly eliminate the main symptoms that cause the most concern to patients, such as pain, functional disorders, fatigue. This action has an inhibitor of Janus kinases 1/ 2 – baricitinib, which quickly reduces the activity of inflammation, provides remission in RA, and has a high analgesic effect. The review discusses the role of autoimmune inflammation and the intracellular signaling pathway JAK/STAT (Janus kinase/signal transducers and activators of transcription) in the pathogenesis of chronic pain in RA, the role of baricitinib for effective control of pain intensity and fatigue. 

ревматоидный артритхроническая больутомляемостьтаргетные синтетические базисные противовоспалительные препаратыЯнус киназабарицитинибRheumatoid arthritischronic painfatiguetargeted synthetic basic anti-inflammatory drugsJAK kinasebaricitinibИсследование выполнено в рамках фундаментальной научной темы № 394 0514-2019-0015 «Контроль боли при ревматических заболеваниях: консервативная терапия и хирургические методы коррекции» (АААА-А19-119021190148-3).ReferencesSmolen J, Aletaha D, Barton A, et al. Rheumatoid Arthritis. Nat Rev Dis Primers. 2018;4:18001. Published 2018 Feb 8. doi:10.1038/nrdp.2018.1Smolen J, Aletaha D, Barton A, et al. Rheumatoid Arthritis. Nat Rev Dis Primers. 2018;4:18001. Published 2018 Feb 8. doi:10.1038/nrdp.2018.1Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-271. https://doi.org/10.14412/1995-4484-2018-263-271Nasonov EL, Olyunin YA, Lila AM. Rheumatoid arthritis: the problems of remission and therapy resistance/ Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2018; 56(3):263-271. (In Russ.). https://doi.org/10.14412/1995-4484-2018-263-271Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. Doi:10.14412/1995-4484-2017-409-419Nasonov EL. Pharmacotherapy for rheumatoid arthritis: new strategy, new targets. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2017;55(4):409-419. (In Russ.). Doi:10.14412/1995-4484-2017-409-419Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. J Clin Med. 2019; 8(7):938. doi: 10.3390/jcm8070938Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. J Clin Med. 2019; 8(7):938. doi: 10.3390/jcm8070938Burmester G, Bijlsma J, Cutolo M, McInnes I. Managing Rheumatic and Musculoskeletal Diseases – Past, Present and Future. Nat Rev Rheumatol. 2017; 13(7):443-448. doi: 10.1038/nrrheum.2017.95Burmester G, Bijlsma J, Cutolo M, McInnes I. Managing Rheumatic and Musculoskeletal Diseases – Past, Present and Future. Nat Rev Rheumatol. 2017; 13(7):443-448. doi: 10.1038/nrrheum.2017.95Van Tuyl LH, Michaud K. Patient-Reported Outcomes in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2016; 42(2):219-37. doi: 10.1016/j.rdc.2016.01.010Van Tuyl LH, Michaud K. Patient-Reported Outcomes in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2016; 42(2):219-37. doi: 10.1016/j.rdc.2016.01.010Fautrel B, Alten R, Kirkham B, et al. Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018; 38(6):935-947. doi: 10.1007/s00296-018-4005-5Fautrel B, Alten R, Kirkham B, et al. Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018; 38(6):935-947. doi: 10.1007/s00296-018-4005-5Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther. 2016; 18(1):114. doi: 10.1186/s13075-016-1004-3Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther. 2016; 18(1):114. doi: 10.1186/s13075-016-1004-3Zhang A, Lee YC. Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization. Curr Osteoporos Rep. 2018;16(5):603-610. doi: 10.1007/s11914-018-0473-5Zhang A, Lee YC. Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization. Curr Osteoporos Rep. 2018;16(5):603-610. doi: 10.1007/s11914-018-0473-5Sharma J, Bhar S, Devi CS. A review on interleukins: The key manipulators in rheumatoid arthritis. Mod Rheumatol. 2017; 27(5):723-746. doi: 10.1080/14397595.2016.1266071Sharma J, Bhar S, Devi CS. A review on interleukins: The key manipulators in rheumatoid arthritis. Mod Rheumatol. 2017; 27(5):723-746. doi: 10.1080/14397595.2016.1266071Ge C, Holmdahl R. The structure, specificity and function of anti-citrullinated protein antibodies. Nat Rev Rheumatol. 2019;15(8):503-508. doi: 10.1038/s41584-019-0244-4Ge C, Holmdahl R. The structure, specificity and function of anti-citrullinated protein antibodies. Nat Rev Rheumatol. 2019;15(8):503-508. doi: 10.1038/s41584-019-0244-4Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing Receptors in Sterile Inflammation and Inflammatory Diseases. Nat Rev Immunol. 2020; 20(2):95-112. doi: 10.1038/s41577-019-0215-7Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing Receptors in Sterile Inflammation and Inflammatory Diseases. Nat Rev Immunol. 2020; 20(2):95-112. doi: 10.1038/s41577-019-0215-7Takeuchi Y, Hirota K, Sakaguch S. Synovial Tissue Inflammation Mediated by Autoimmune T Cells. Front Immunol. 2019;10:1989. doi: 10.3389/fimmu.2019.01989.Takeuchi Y, Hirota K, Sakaguch S. Synovial Tissue Inflammation Mediated by Autoimmune T Cells. Front Immunol. 2019;10:1989. doi: 10.3389/fimmu.2019.01989.Nagata S. Apoptosis and Clearance of Apoptotic Cells. Annu Rev Immunol. 2018 Apr 26;36:489-517. doi: 10.1146/annurev-immunol-042617-053010Nagata S. Apoptosis and Clearance of Apoptotic Cells. Annu Rev Immunol. 2018 Apr 26;36:489-517. doi: 10.1146/annurev-immunol-042617-053010Smith Jr T, Tharakan A, Martin R. Targeting ADAM10 in Cancer and Autoimmunity. Front Immunol. 2020; 11:499. doi: 10.3389/fimmu.2020.00499Smith Jr T, Tharakan A, Martin R. Targeting ADAM10 in Cancer and Autoimmunity. Front Immunol. 2020; 11:499. doi: 10.3389/fimmu.2020.00499Deane K, Holers V. The Natural History of Rheumatoid Arthritis. Clin Ther. 2019;41(7):1256-1269. doi: 10.1016/j.clinthera.2019.04.028Deane K, Holers V. The Natural History of Rheumatoid Arthritis. Clin Ther. 2019;41(7):1256-1269. doi: 10.1016/j.clinthera.2019.04.028Uciechowski P, Dempke W. Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020; 98(3):131-137. doi: 10.1159/000505099Uciechowski P, Dempke W. Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020; 98(3):131-137. doi: 10.1159/000505099Crotti C, Agape E, Becciolini A, Biggioggero M, Favalli EG. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. Drugs. 2019; 79(16):1741-1755. doi: 10.1007/s40265-019-01192-zCrotti C, Agape E, Becciolini A, Biggioggero M, Favalli EG. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. Drugs. 2019; 79(16):1741-1755. doi: 10.1007/s40265-019-01192-zKatz EJ, Gold MS. Inflammatory hyperalgesia: a role for the C-fiber sensory neuron cell body? J Pain. 2006; 7(3):170-8. doi: 10.1016/j.jpain.2005.10.003Katz EJ, Gold MS. Inflammatory hyperalgesia: a role for the C-fiber sensory neuron cell body? J Pain. 2006; 7(3):170-8. doi: 10.1016/j.jpain.2005.10.003Chen X, Alessandri-Haber N, Levine JD. Marked attenuation of inflammatory mediator-induced C-fiber sensitization for mechanical and hypotonic stimuli in TRPV4-/- mice. Mol Pain. 2007; 3:31. doi: 10.1186/1744-8069-3-31Chen X, Alessandri-Haber N, Levine JD. Marked attenuation of inflammatory mediator-induced C-fiber sensitization for mechanical and hypotonic stimuli in TRPV4-/- mice. Mol Pain. 2007; 3:31. doi: 10.1186/1744-8069-3-31Lee C-H, Giuliani F. The Role of Inflammation in Depression and Fatigue. Front Immunol. 2019 Jul 19;10:1696. doi: 10.3389/fimmu.2019.01696Lee C-H, Giuliani F. The Role of Inflammation in Depression and Fatigue. Front Immunol. 2019 Jul 19;10:1696. doi: 10.3389/fimmu.2019.01696Kim K-H, Seo H-J, Abdi S., Huh B. All About Pain Pharmacology: What Pain Physicians Should Know. Korean J Pain. 2020;33(2):108-120. doi: 10.3344/kjp.2020.33.2.108Kim K-H, Seo H-J, Abdi S., Huh B. All About Pain Pharmacology: What Pain Physicians Should Know. Korean J Pain. 2020;33(2):108-120. doi: 10.3344/kjp.2020.33.2.108Harth M, Nielson WR. Pain and affective distress in arthritis: relationship to immunity and inflammation. Expert Rev Clin Immunol. 2019; 15(5):541-552. doi: 10.1080/1744666X.2019.1573675Harth M, Nielson WR. Pain and affective distress in arthritis: relationship to immunity and inflammation. Expert Rev Clin Immunol. 2019; 15(5):541-552. doi: 10.1080/1744666X.2019.1573675Yang S, Chang M. Chronic Pain: Structural and Functional Changes in Brain Structures and Associated Negative Affective States. Int J Mol Sci. 2019; 20(13):3130. doi: 10.3390/ijms20133130Yang S, Chang M. Chronic Pain: Structural and Functional Changes in Brain Structures and Associated Negative Affective States. Int J Mol Sci. 2019; 20(13):3130. doi: 10.3390/ijms20133130Zhao SS, Duffield SJ, Goodson NJ. The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol. 2019;33(3):101423. doi: 10.1016/j.berh.2019.06.005Zhao SS, Duffield SJ, Goodson NJ. The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol. 2019;33(3):101423. doi: 10.1016/j.berh.2019.06.005Dougados M, Perrot S. Fibromyalgia and central sensitization in chronic inflammatory joint diseases. Joint Bone Spine. 2017; 84(5):511-513. doi: 10.1016/j.jbspin.2017.03.001Dougados M, Perrot S. Fibromyalgia and central sensitization in chronic inflammatory joint diseases. Joint Bone Spine. 2017; 84(5):511-513. doi: 10.1016/j.jbspin.2017.03.001Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 5): v29-v34. doi: 10.1093/rheumatology/kez346Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 5): v29-v34. doi: 10.1093/rheumatology/kez346Daviu N, Bruchas M, Moghaddam B, Sandi C, Beyeler A. Neurobiological Links Between Stress and Anxiety. Neurobiol Stress. 2019; 11:100191. doi: 10.1016/j.ynstr.2019.100191.Daviu N, Bruchas M, Moghaddam B, Sandi C, Beyeler A. Neurobiological Links Between Stress and Anxiety. Neurobiol Stress. 2019; 11:100191. doi: 10.1016/j.ynstr.2019.100191.Maloley PM, England BR, Sayles H, et al. Post-traumatic stress disorder and serum cytokine and chemokine concentrations in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019; 49(2):229-235. doi: 10.1016/j.semarthrit.2019.02.002Maloley PM, England BR, Sayles H, et al. Post-traumatic stress disorder and serum cytokine and chemokine concentrations in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019; 49(2):229-235. doi: 10.1016/j.semarthrit.2019.02.002Tiosano S, Yavne Y, Watad A, et al. The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis.Eur J Clin Invest. 2020 Jun 1:e13268. doi: 10.1111/eci.13268Tiosano S, Yavne Y, Watad A, et al. The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis.Eur J Clin Invest. 2020 Jun 1:e13268. doi: 10.1111/eci.13268Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018;22(2):216-241. doi: 10.1002/ejp.1140Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018;22(2):216-241. doi: 10.1002/ejp.1140Kaplan C, Minc A, Basu N, Schrepf A. Inflammation and the Central Nervous System in Inflammatory Rheumatic Disease. Curr Rheumatol Rep. 2019;21(12):67. doi: 10.1007/s11926-019-0870-5Kaplan C, Minc A, Basu N, Schrepf A. Inflammation and the Central Nervous System in Inflammatory Rheumatic Disease. Curr Rheumatol Rep. 2019;21(12):67. doi: 10.1007/s11926-019-0870-5Kiguchi N, Kobayashi D, Saika F, Matsuzaki S, Kishioka S. Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages. Int J Mol Sci. 2017;18(11):2296. doi: 10.3390/ijms18112296Kiguchi N, Kobayashi D, Saika F, Matsuzaki S, Kishioka S. Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages. Int J Mol Sci. 2017;18(11):2296. doi: 10.3390/ijms18112296Siouti E, Andreakos E. The many facets of macrophages in rheumatoid arthritis. Biochem Pharmacol. 2019;165:152-169. doi: 10.1016/j.bcp.2019.03.029Siouti E, Andreakos E. The many facets of macrophages in rheumatoid arthritis. Biochem Pharmacol. 2019;165:152-169. doi: 10.1016/j.bcp.2019.03.029Kothari P, Pestana R, Mesraoua R, et al. IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAKdependent IL-10 expression in macrophages. J Immunol. 2014;192(1):349-57. doi: 10.4049/jimmunol.1301906Kothari P, Pestana R, Mesraoua R, et al. IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAKdependent IL-10 expression in macrophages. J Immunol. 2014;192(1):349-57. doi: 10.4049/jimmunol.1301906Salaffi F, Giacobazzi G, Di Carlo M. Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway. Pain Res Manag. 2018;2018:8564215Salaffi F, Giacobazzi G, Di Carlo M. Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway. Pain Res Manag. 2018;2018:8564215Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуно-воспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi:10.14412/1995-4484-2019-8-16.Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2019;57(1):8-16. (In Russ.). doi:10.14412/1995-4484-2019-8-16.Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-wVirtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333-wPark SJ, Lee JH, Kim HY, et al. Astrocytes, but not microglia, rapidly sense H₂O₂via STAT6 phosphorylation, resulting in cyclooxygenase-2 expression and prostaglandin release. J Immunol. 2012;188(10):5132-5141. doi:10.4049/jimmunol.1101600Park SJ, Lee JH, Kim HY, et al. Astrocytes, but not microglia, rapidly sense H₂O₂via STAT6 phosphorylation, resulting in cyclooxygenase-2 expression and prostaglandin release. J Immunol. 2012;188(10):5132-5141. doi:10.4049/jimmunol.1101600Ding CP, Guo YJ, Li HN, et al. Red nucleus interleukin-6 participates in the maintenance of neuropathic pain through JAK/ STAT3 and ERK signaling pathways. Exp Neurol. 2018 Feb;300:212-221. DOI: 10.1016/j.expneurol.2017.11.012Ding CP, Guo YJ, Li HN, et al. Red nucleus interleukin-6 participates in the maintenance of neuropathic pain through JAK/ STAT3 and ERK signaling pathways. Exp Neurol. 2018 Feb;300:212-221. DOI: 10.1016/j.expneurol.2017.11.012Xu Z, Wu H, Zhang H, Bai J, Zhang Z. Interleukins 6/8 and cyclooxygenase-2 Release and Expressions Are Regulated by Oxidative stress-JAK2/STAT3 Signaling Pathway in Human Bronchial Epithelial Cells Exposed to Particulate Matter ≤2.5 μm. J Appl Toxicol. 2020 Mar 24. doi: 10.1002/jat.3977Xu Z, Wu H, Zhang H, Bai J, Zhang Z. Interleukins 6/8 and cyclooxygenase-2 Release and Expressions Are Regulated by Oxidative stress-JAK2/STAT3 Signaling Pathway in Human Bronchial Epithelial Cells Exposed to Particulate Matter ≤2.5 μm. J Appl Toxicol. 2020 Mar 24. doi: 10.1002/jat.3977Choy EHS, Miceli-Richard C, González-Gay MA, et al. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin Exp Rheumatol. 2019;37(4):694- 704Choy EHS, Miceli-Richard C, González-Gay MA, et al. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin Exp Rheumatol. 2019;37(4):694- 704Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2020;58(3):304-316. doi:10.14412/1995-4484-2020-304-316Nasonov EL, Lila AM. Baricitinib: new pharmacotherapy options for rheumatoid arthritis and other immune-mediated inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2020;58(3):304-316. (In Russ.). doi:10.14412/1995-4484-2020-304-316Pope J, Sawant R, Tundia N, et al. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Adv Ther. 2020;37(5):2356-2372. doi: 10.1007/s12325-020-01303-3Pope J, Sawant R, Tundia N, et al. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Adv Ther. 2020;37(5):2356-2372. doi: 10.1007/s12325-020-01303-3Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-662. doi: 10.1056/NEJMoa1608345Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-662. doi: 10.1056/NEJMoa1608345Keystone EC, Taylor PC, Tanaka Y., et al. Patient-reported Outcomes From a Phase 3 Study of Baricitinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: Secondary Analyses From the RA-BEAM Study. Ann Rheum Dis. 2017;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259Keystone EC, Taylor PC, Tanaka Y., et al. Patient-reported Outcomes From a Phase 3 Study of Baricitinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: Secondary Analyses From the RA-BEAM Study. Ann Rheum Dis. 2017;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259Taylor PC, Lee YC, Fleischmann R, et al. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. J Clin Med. 2019;8(6). pii: E831. doi: 10.3390/jcm8060831Taylor PC, Lee YC, Fleischmann R, et al. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. J Clin Med. 2019;8(6). pii: E831. doi: 10.3390/jcm8060831Smolen JS, Kremer JM, Gaich CL, et al. Patient-reported Outcomes From a Randomised Phase III Study of Baricitinib in Patients With Rheumatoid Arthritis and an Inadequate Response to Biological Agents (RA-BEACON). Ann Rheum Dis. 2017;76(4):694-700. doi: 10.1136/annrheumdis-2016-209821Smolen JS, Kremer JM, Gaich CL, et al. Patient-reported Outcomes From a Randomised Phase III Study of Baricitinib in Patients With Rheumatoid Arthritis and an Inadequate Response to Biological Agents (RA-BEACON). Ann Rheum Dis. 2017;76(4):694-700. doi: 10.1136/annrheumdis-2016-209821Fautrel B, Zhu B, Taylor PC, et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. RMD Open. 2020;6(1). pii: e001131. doi: 10.1136/rmdopen-2019-001131Fautrel B, Zhu B, Taylor PC, et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. RMD Open. 2020;6(1). pii: e001131. doi: 10.1136/rmdopen-2019-001131

The authors declare that there are no conflicts of interest present.